NCT00847015

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Phase II Study of Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out if using the combination of standard chemotherapy (gemcitabine and cisplatin) plus this new targeted pill (sunitinib) can help shrink your tumor before you undergo surgery for your bladder cancer.

Conditions

• Bladder Cancer
• Urinary Bladder

Interventions

Type	Name	Description
DRUG	Sunitinib	Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
DRUG	Gemcitabine	Gemcitabine 1,000 mg/m\^2
DRUG	cisplatin	cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.

Timeline

• Start date: 2009-02-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2009-02-19
• Last updated: 2016-02-29
• Results posted: 2016-02-29

Locations

5 sites across 1 country: United States